Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

The study, published in Nature Medicine, analysed genetic information from more than 200 patients undergoing treatment for melanoma (one of the most common skin cancers), to find stretches of DNA that correlated with whether the patient developed severe side-effects from the treatment.

Cancer immunotherapy is central to the medical management of melanoma, being used to reduce the risk of melanoma returning after surgery, but also when it has spread around the body. The most common immunotherapy involves patients being given drugs called ‘checkpoint inhibitors’, which help stimulate the immune system and are given as infusions through a drip. Whilst checkpoint immunotherapy has revolutionised melanoma treatment, a subset of patients will develop serious side-effects due to their immune system attacking other tissues and organs.  This can lead to diverse symptoms, including diarrhoea, lung inflammation and joint and muscle pain.  Whilst these are typically transient, patients may require strong steroid medication to dampen their immune responses and often have to stop immunotherapy altogether. In rare cases these side-effects can be life-threatening. Currently clinicians have no way of predicting who will develop such side-effects, and also have very limited insights into the way side-effects develop.

In this latest research a study from the Dana Faber Cancer Institute, co-published in Nature Medicine, identified a change in the genetic code of the IL7 gene - with patients carrying this significantly more likely to develop side-effects. The paper from the Oxford team, led by Associate Professor Ben Fairfax from the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, was able to replicate the Dana Faber findings, and extended the work by showing the immunological consequences of this change.

Speaking about the work, Prof Fairfax said: “We found individuals carrying this genetic variant, which is present in about 8% of patients treated for melanoma, were about six times more likely to develop side effects severe enough to require steroids. Furthermore, we found this genetic variant alters the amount of IL7 code produced by B cells – a cell type normally associated with making antibodies, so to see the genetic effect acting in these cells was surprising”. 

Interestingly, the Oxford University researchers found that the effect of this genetic change was detectable in B cells before immunotherapy was given, suggesting B cells play an important role in the immune response to untreated skin cancer. Supporting this, they found in analysis of historical samples from patients with melanoma, that the genetic change appeared to be naturally protective against the melanoma recurrence.  

Professor Fairfax said “what is fascinating is that whilst patients with this genetic risk variant were more likely to get side-effects from immunotherapy, both groups found that patients with this change appeared independently to have less chance of the cancer returning”. He added: “whilst it is important to emphasise that if a patient carries this genetic marker it doesn’t guarantee that they’ll have serious side-effects after cancer immunotherapy or vice versa, we think that this work might enable a genetic test to help patients with melanoma, in discussion with their doctors, decide the treatment best for them. We also believe these observations can guide new treatment development for melanoma when it has spread.”

The study was carried out in conjunction with the Oxford Skin Cancer clinical team at the Churchill Hospital, led by Dr Miranda Payne. She said: “This work would not have been possible without the close working relationship we have with researchers in the University, as well as the incredible generosity of all our patients who have contributed samples. We are hugely grateful because these results represent a step-change in our understanding of who may be most at risk from some of our treatments. .. The more individualised our understanding of our patients’ risks from immunotherapy, the easier it will be to guide them through the complex treatment decisions they may have to face.’

The full paper, ''IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma' can be read in Nature Medicine.

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.